alendronate has been researched along with Arthritis in 8 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Arthritis: Acute or chronic inflammation of JOINTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We present a case of acute polyarthritis after administration of alendronate and risedronate in a 52-year-old woman." | 7.83 | Alendronate- and risedronate-induced acute polyarthritis. ( Uğurlar, M, 2016) |
| "We describe 7 cases of synovitis or arthritis occurring after commencement of alendronate for treatment of osteoporosis." | 7.74 | Alendronate-induced synovitis. ( Gwynne Jones, DP; Highton, J; Savage, RL, 2008) |
| " We present a case of acute polyarthritis after administration of alendronate and risedronate in a 52-year-old woman." | 3.83 | Alendronate- and risedronate-induced acute polyarthritis. ( Uğurlar, M, 2016) |
| "We describe 7 cases of synovitis or arthritis occurring after commencement of alendronate for treatment of osteoporosis." | 3.74 | Alendronate-induced synovitis. ( Gwynne Jones, DP; Highton, J; Savage, RL, 2008) |
| "Dermatomyositis is an inflammatory autoimmune condition that has also been associated with malignancy." | 2.47 | Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought. ( Fett, N; Liu, RH, 2011) |
| "Alendronate was administered at 100 μg/kg, orally, once a day." | 1.38 | Downregulation of the inflammatory response by CORM-3 results in protective effects in a model of postmenopausal arthritis. ( Alcaraz, MJ; Caeiro, JR; Ferrándiz, ML; Guede, D; Ibáñez, L; Maicas, N; Motterlini, R, 2012) |
| " After 1 month of Alendronate, an aminobisphosphonate, given at a dosage of 10 mg once a week intravenously for the first 6 weeks and then once a month thereafter, the arthritis and skin nodules improved, and the remission has continued for more than 2 years." | 1.32 | Successful treatment of multicentric reticulohistiocytosis with alendronate: evidence for a direct effect of bisphosphonate on histiocytes. ( Goto, H; Imanishi, Y; Inaba, M; Inui, K; Kobayashi, K; Kumeda, Y; Nishizawa, Y; Okada, F, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uğurlar, M | 1 |
| Fett, N | 1 |
| Liu, RH | 1 |
| Ibáñez, L | 1 |
| Alcaraz, MJ | 1 |
| Maicas, N | 1 |
| Guede, D | 1 |
| Caeiro, JR | 1 |
| Motterlini, R | 1 |
| Ferrándiz, ML | 1 |
| Goto, H | 1 |
| Inaba, M | 1 |
| Kobayashi, K | 1 |
| Imanishi, Y | 1 |
| Kumeda, Y | 1 |
| Inui, K | 1 |
| Okada, F | 1 |
| Nishizawa, Y | 1 |
| Gerster, JH | 1 |
| Frederiksen, L | 1 |
| Junker, P | 1 |
| Brixen, KT | 1 |
| Gwynne Jones, DP | 1 |
| Savage, RL | 1 |
| Highton, J | 1 |
| Schwarz, EM | 1 |
| Benz, EB | 1 |
| Lu, AP | 1 |
| Goater, JJ | 1 |
| Mollano, AV | 1 |
| Rosier, RN | 1 |
| Puzas, JE | 1 |
| Okeefe, RJ | 1 |
1 review available for alendronate and Arthritis
| Article | Year |
|---|---|
Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought.
Topics: Alendronate; Antineoplastic Protocols; Arthritis; Breast Neoplasms; Combined Modality Therapy; Derma | 2011 |
7 other studies available for alendronate and Arthritis
| Article | Year |
|---|---|
Alendronate- and risedronate-induced acute polyarthritis.
Topics: Alendronate; Arthritis; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteoporosis, | 2016 |
Downregulation of the inflammatory response by CORM-3 results in protective effects in a model of postmenopausal arthritis.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Arthritis; Biomarkers; Disease Models, Animal; Down- | 2012 |
Successful treatment of multicentric reticulohistiocytosis with alendronate: evidence for a direct effect of bisphosphonate on histiocytes.
Topics: Adult; Alendronate; Arthritis; Female; Histiocytes; Histiocytosis, Non-Langerhans-Cell; Humans; Skin | 2003 |
Acute polyarthritis related to once-weekly alendronate in a woman with osteoporosis.
Topics: Acute Disease; Alendronate; Arthralgia; Arthritis; Drug Administration Schedule; Female; Humans; Joi | 2004 |
[Persistent polyarticular synovitis after treatment with alendronate].
Topics: Alendronate; Arthritis; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteoporosis, | 2007 |
Alendronate-induced synovitis.
Topics: Aged; Alendronate; Arthritis; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteopo | 2008 |
Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis.
Topics: Alendronate; Animals; Arthritis; Arthroplasty; Cell Division; Disease Models, Animal; Female; Male; | 2000 |